Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

← catalyst calendar

NCT07227298 · readout in 932 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

162estimated

Sites

Countries

China, France, Germany +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-01-30

actual

When the study began enrolling

Primary completion

2029-03-08

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2033-08-23

estimated

The whole study's end, after follow-up

First posted

2025-11-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Cancer

Interventions

Biological: PF-08634404 — also filed as SSGJ-707
Biological: Sigvotatug Vedotin — also filed as SGN-B6A, PF-08046047
Biological: Combination Agent 1

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

measured Through 90 days after the last study intervention; Up to approximately 5 years

Phase I: Number of participants with dose limiting toxicity (DLT)

measured Through 90 days after the last study intervention; Up to approximately 5 years

Phase 2: Confirmed Objective Response Rate (ORR) per RECIST v1.1 by investigator

measured Up to approximately 5 Years

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed